

ATTEMPTED SYNTHESIS OF QUINONEMETHINE DERIVATIVE OF NOCARDICIN A ANALOGUES

G. H. Hakimelahi and A. Khalafi-Nezhad

Department of Chemistry, Faculty of Science, University of Shiraz, Shiraz, Iran



Keywords: β -lactams, Nocardicin, 2-Azetidenone

Abstract


The synthesis of some β -lactams is described. The electronic activation of monocyclic β -lactams provided by a quinonemethine function was found to instabilize the β -lactam ring toward nucleophilic attack by water.

The essential features of the classical β -lactam antibiotics penicillin I and cephalosporin II are (a) a *cis*-fused β -lactam ring; (b) an acylamino side chain which can be considerably varied; (c) an acidic function; (d) a five-membered ring or a six-membered ring containing a double bond conjugated with the β -lactam nitrogen conferring enough ring strain so as to raise the β -lactam frequency to $\geq 1765 \text{ cm}^{-1}$. It has been shown that the sulfur atom can be replaced by oxygen or carbon without substantial loss of antimicrobial activity [1].

The IR. absorption frequency of the carbonyl of a β -lactam can also be considered as a measure of its reactivity towards nucleophilic attack [2], therefore higher frequency might indicate the potential for higher biological activity. The synthesis of several monocyclic nuclear analogues of β -lactam antibiotics, in which the ring strain of fused β -lactams was replaced by electronic activation has been reported [3,4].




Nocardicin A [5] III, the first monocyclic β -lactam antibiotic described, is remarkably active against Gram-negative organisms *in vivo* [6] although it



III $R^1 = \text{H}, R^2 = \text{H}$

IV $R^1 = \text{OH}, R^2 = \text{CH}_2\text{OH}$



displays but little activity *in vitro* [7,8]. It differs from all hitherto described β -lactam antibiotics, 1770-1780 cm^{-1} , in having a relatively unstrained (1725 cm^{-1}) β -lactam ring, and therefore being quite stable towards nucleophilic attack. It occurred to us that the *in vivo* activation may well be linked to an oxidation of nocardicin A to the corresponding quinonemethine, in which the β -lactam frequency should be considerably augmented, thus leading to a chemically and therefore perhaps biologically reactive lactam. Due to the difficulties in preparing quinonemethines [9], we reported [10,11] nocardicin analogues bearing two ortho-related hydroxyl groups in which an *in vivo* and/or an *in vitro* oxidation to an ortho-quinone may be more easily achieved. The prepared compound IV showed no significant antibacterial activity *in vitro*. However, this does not rule out the aforementioned *vivo* oxidation, of nocardicin A, presumption.

We now report an attempt for the synthesis of β -lactam 8, in which the electronic activation is provided by a quinonemethine function. Schiff base 1 was prepared [12] in high yield from benzylamine and methyl glyoxylate [13]. A t-butanol solution of 1 was treated for 1h with one equiv. of dimethylphosphite and one equiv. of potassium t-butoxide to afford benzylamine 2 (50%). Catalytic debenzoylation of its hydrochloride salt provided methyl α -aminodimethyl-

phosphonoacetate 3 (80%). Compound 3 was converted to its cinnamylidene Schiff base which upon treatment with azidoacetyl chloride [14] using the methods described by Doyle et al [15], gave β -lactam 4 as a mixture of epimers at the carboxyl bearing carbon. The β -lactam obtained by this method was *cis* fused, as could be determined by NMR. ($J=5$ Hz) of all derivatives in which the relevant protons did not overlap with other signals. The azide function in 4 was reduced with $\text{H}_2\text{S}/\text{NEt}_3$ [16], and the resulting amine directly acylated with phenylacetyl chloride in the presence of pyridine to give amide 5 (70%). Reaction of 5 with 6 by means of NaH in tetrahydrofuran (THF) at -15° afforded β -lactam 7 ($\sim 15\%$). Although compound 7 in methanol was unstable and the β -lactam ring function was opened within 5 to 10 min., in water it was found to be more stable (T/2 5h).

All attempts to convert 7 to the corresponding quinonemethine 8 resulted in the destruction of the β -lactam ring.

Experimental Section

General Procedure: See ref. 17.

Benzylaminophosphonate 2. To a solution of methyl glyoxylate (0.88 g, 0.01 mol) in 50 ml dry CH_2Cl_2

was added benzyl amine (1.07 g, 0.01 mol) and MgSO_4 . After stirring for 20 h, it was filtered and evaporated to yield Schiff base **1** quantitatively as an oil. NMR. (CDCl_3): δ 7.64 (m, 1H, N=CH), 7.43 (s, 5H, Ph), 4.91 (d, 2H, CH_2 , $J=1\text{Hz}$), 4.10 (s, 3H, Me). IR. (CH_2Cl_2): 1735, 1711, 1643 cm^{-1} .

To a solution of **1** (1.77 g, 0.01 mol) and dimethyl phosphite (1.10g, 0.01 mol) in 30 ml t-butanol, t-BuOK (1.12 g, 0.01 mol) was added. After stirring for 2h, it was evaporated to dryness and the residue was dissolved in ether, washed with water and dried (MgSO_4). Filtration and evaporation gave crude product **2**. Purification by column chromatography using Al_2O_3 , and elution with CHCl_3 gave **2** in 50% yield. NMR. (CDCl_3): δ 7.35 (s, 5H, Ph), 3.85-4.50 (3s, 9H, 3Me), 3.79 (d, 2H, CH_2 , $J=2\text{Hz}$), 3.58 (d, 1H, CH, $J=20\text{Hz}$), 2.37 (b, 1H, NH, exchangeable with D_2O). IR. (CH_2Cl_2): 3230-3550, 1729 cm^{-1} . MS: 287 (M^+).

2.HCl was prepared by the addition of a saturated ethereal solution of HCl to an ethereal solution of compound **2**.

Methyl a-amino-a-dimethylphosphonoacetate (3). Compound **2**. HCl (3.225 g, 0.01 mol) was dissolved in 60 ml oxygen free methanol. Pd/C (10%, 0.4 g) was added, and the mixture was hydrogenated at 25 °C and 45 Psi for 3 h. The solution was then filtered and evaporated to afford a compound **3.HCl** (80%). NMR. (CDCl_3): δ 8.51-8.95 (b, 3H, NH_3^+Cl^- , exchanged with D_2O), 5.05 (d, 1H, CH, $J=20\text{Hz}$), 3.90-4.49 (3s, 9H, 3Me).

Conversion of **3.HCl** to aminophosphonate **3** was achieved by addition of an aq. solution of K_2HPO_4 (PH=9.3, 10ml) to 1.5 g **3.HCl**, followed by extraction with EtOAc. The organic layer was dried (MgSO_4), filtered and evaporated to give **3** (80%). NMR. (CDCl_3): δ 3.85 -4.35 (3s, 9H, 3Me), 4.01 (d, 1H, CH, $J=20\text{Hz}$), 2.25 (b, 2H, NH_2 , exchanged with D_2O). IR. (CH_2Cl_2): 3350-3410, 1738 cm^{-1} . CI.-MS.: 198 ($\text{M}^+ + 1$).

Preparation of methyl 2-(3-azido-2-Oxo-4-styryl-1-azetidiny)-2-dimethylphosphonoacetate (4). To a solution of aminophosphonate (**3**, 1.97 g, 0.01 mol) in 40 ml dry CH_2Cl_2 was added cinnamaldehyde (1.6 g, 0.012 mol), and magnesium sulfate (10 g) After stirring at 25 °C for 3 h the mixture was filtered. Triethylamine (1.01 g, 0.01 mol) was added, followed by the dropwise addition of azidoacetyl chloride (1.20g, 0.01 mol) at 25 °C. After stirring for 1 h, the solution was washed with water, dried and evaporated to give the crude β -lactam which was purified by column chromatography on silica gel. Elution with CH_2Cl_2 gave **3g** (80%) of the oily azido

β -lactam **4** as a mixture of two diastereoisomers. NMR. (CDCl_3): δ 7.35 (m, 5H, Ph), 6.12-6.98 (m, 2H, CH=CH), 4.91 (m, 2H, H-C (3,4)), 4.80 (d, $J=22\text{Hz}$, 1H, CH), 3.58-4.21 (m, 9H, 3Me). IR (CH_2Cl_2): 2100 (N_3), 1765 (β -lactam), 1745 (ester) cm^{-1} . CI.-MS.: 395 ($\text{M}^+ + 1$).

Preparation of methyl 2-(2-Oxo-3-Phenylacetamido-4-styryl-1-azetidiny)-2-dimethylphosphonoacetate (5). Triethylamine (0.6 g, 0.006 mol) was added to a solution of a diastereoisomeric mixture of **4** (1.97 g, 0.005 mol) in 50 ml of dry CH_2Cl_2 at 0 °C and H_2S was bubbled in for 35 min. The solution was allowed to stand for 2 h at 25 °C. Nitrogen was bubbled in for 30 min. Then was added (1.3 g, 0.015 mol) pyridine, followed by the dropwise addition of 0.9 g (0.006 mol) phenylacetyl chloride in 20 ml CH_2Cl_2 . The solution was stirred for 2 h at 25 °C, then washed with 10% HCl, 10% of NaHCO_3 and water, dried (MgSO_4), and evaporated to give the impure amide **5** which was chromatographed on silica gel. CH_2Cl_2 eluted impurities, and $\text{CHCl}_3/\text{EtOAc}$ (1:5) gave 2.31 g (90%) of β -lactam **5**, a mixture of diastereoisomers, as an oil. NMR. (CDCl_3): δ 7.81 (d, 1H, NH), 7.35 (s, 5H, Ph-C=C), 7.03 (s, 5H, Ph), 5.88-6.89 (m, 2H, CH=CH), 5.40-5.63 (m, 1H, CHN), 4.63-5.35 (m, 2H, PCH and CH-C=C), 3.68-4.12 (m, 9H, 3Me), 3.46 (s, 2H, CH_2Ph). IR. (CH_2Cl_2): 3410 (NH), 1770 (β -lactam), 1740 (ester), 1685 (amide) cm^{-1} . CI.-MS.: 458 ($\text{M}^+ + 1$).

Preparation of β -lactam 7. To a solution of **5** (4.57g, 0.01 mol) and **6** (1.54g, 0.01 mol) in 70 ml THF at -15 °C was added NaH (0.01 mol). The solution was stirred for 2 h at the same temperature and then at 25 °C for a further 4 h. The reaction mixture was quenched with aq. NH_4Cl -solution and extracted with CH_2Cl_2 . The crude product was purified with silica gel using CH_2Cl_2 as eluent to afford β -lactam **7** in about 15% yield. NMR. (CDCl_3): δ 7.72 (d, 1H, NH), 5.91-7.39 (m, 16H, 2Ph and 6 CH=C), 5.45 (d x d, $J=5$ and 10 Hz, 1H, H-C (3)), 4.89 (br., 1H, H-C(4)), 4.00-4.50 (3s, 9H, Me), 3.61 (s, 2H, CH_2Ph). IR. (CH_2Cl_2): 3400 (NH), 1800 (β -lactam), 1756 (ester), 1680 (amide).

Acknowledgements

We wish to thank the Shiraz University Research Council for their generous financial support and Mr. Ketabchi for his technical assistance.

References

1. R.A. Firestone, J.L. Fahey, N.S. Maciejewicz, G.S. Pater, and B.G. Christensen, *J. Med. Chem.* **20**, 551 (1977).
2. R.B. Morin, B.G. Jackson, R.A. Mueller, E.R. Lavagnino, W.B. Scanlon, and S.L. Andrews, *J. Am. Chem. Soc.*, **91**, 1401 (1969).
3. G. Lowe, and D.D. Ridley, *J. Chem. Soc., Perkin Trans. I*, 2024 (1973).
4. G.H. Hakimelahi, *Helv. Chim. Acta* **65**, 1378 (1982).
5. H. Aoki, H. Sakai, M. Kohsaka, T. Konomi, J. Hosoda, T. Kubochi, E. Iguchi, and H. Imanaka, *J. Antibiot.*, **29**, 492 (1976).
6. Y. Mine, S. Nonoyama, H. Kojo, S. Fukada, M. Nishida, S. Goto, and S. Kuwahara, *ibid*, **30**, 932 (1977).
7. Y. Mine, S. Nonoyama, H. Kojo, S. Fukada, M. Nishida, S. Goto, and S. Kuwahara, *ibid*, **30**, 917 (1977).
8. H. Kojo, Y. Mine, M. Nishida, and T. Yokota, *ibid*, **30**, 926 (1977).
9. D.J. Hart, P.A. Cain, and D.A. Evans, *J. Am. Chem. Soc.*, **100**, 1548 (1978).
10. G.H. Hakimelahi, and G. Just, *Can. J. Chem.*, **57**, 1932 (1979).
11. G.H. Hakimelahi, and G. Just, *ibid*, **57**, 1939 (1979).
12. W.F. Huffman, K.G. Holden, T.F. Buckley, J.G. Gleason, and L. Wu, *J. Am. Chem. Soc.*, **99**, 2352 (1977).
13. J. Blake, J.R. Tretter, G.J. Juhasz, W. Bonthron, and H. Rapoport, *ibid*, **88**, 4061 (1966).
14. A.K. Bose, M.S. Manhas, J.S. Chib, J.P.S. Chawla, and B. Dayal, *J. Org. Chem.*, **39**, 2877 (1974).
15. T.W. Doyle, B. Belleau, B. Yuluh, C.F. Ferrari, and M.P. Cunningham, *Can. J. Chem.*, **55**, 468 (1977).
16. G. Just, and T. J. Liak, *ibid* **56**, 211 (1978).
17. G.H. Hakimelahi, C.B. Boyce, and H.S. Kasmai, *Helv. Chim. Acta* **60**, 342 (1977).